Locations:
Search
Rebound risk is shaped by patient characteristics and mechanism of action of current DMT
First-of-kind prediction model demonstrates high consistency across internal and external validation
Real-world study also finds no significant rise in ocrelizumab-related risk with advanced age
Machine learning study associates discrete neuropsychological testing profiles with neurodegeneration
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Study highlights value of sleep disorder screening and targeted management strategies
Despite less overall volume loss than in MS and NMOSD, volumetric changes correlate with functional decline
A passionate specialist surveys the field’s past, present and future
Program participation correlates with reduced use of opioids, X-rays and ED visits
This MRI marker of inflammation can help differentiate MS from mimics early in the disease
Novel approach dramatically reduces the need for real-world data in diverse clinical populations
Advertisement
Advertisement